Covered recipient · General Payments record
ANNE M MAI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$1,654.19
- Reported across 68 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,227.30 | 52 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $306.62 | 15 |
| Lilly USA, LLC | $135.44 | 6 |
| Celgene Corporation | $133.24 | 8 |
| ARGENX US, INC. | $103.72 | 3 |
| UCB, Inc. | $83.33 | 3 |
| EISAI INC. | $81.23 | 3 |
| EMD Serono, Inc. | $68.98 | 2 |
| Lundbeck LLC | $67.60 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $51.98 | 2 |
| Alnylam Pharmaceuticals Inc. | $51.00 | 2 |
| ACADIA Pharmaceuticals Inc | $31.46 | 1 |
| Biogen, Inc. | $28.74 | 1 |
| PFIZER INC. | $26.19 | 1 |
| Neurelis, Inc. | $24.41 | 1 |
| Alexion Pharmaceuticals, Inc. | $18.26 | 1 |
| Teva Pharmaceuticals USA, Inc. | $15.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (52)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2018201920222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.21 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931043 | CMS |
| ABBVIE INC. | $25.27 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931047 | CMS |
| ABBVIE INC. | $34.13 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931051 | CMS |
| ABBVIE INC. | $10.00 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931055 | CMS |
| ABBVIE INC. | $15.05 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931059 | CMS |
| ABBVIE INC. | $23.15 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931063 | CMS |
| ABBVIE INC. | $29.72 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931066 | CMS |
| ABBVIE INC. | $6.98 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931070 | CMS |
| ABBVIE INC. | $16.53 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931074 | CMS |
| ABBVIE INC. | $29.67 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931079 | CMS |
| ABBVIE INC. | $13.56 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931083 | CMS |
| ABBVIE INC. | $31.28 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931087 | CMS |
| ABBVIE INC. | $12.78 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931091 | CMS |
| ABBVIE INC. | $14.72 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931095 | CMS |
| ABBVIE INC. | $29.57 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931099 | CMS |
| ACADIA Pharmaceuticals Inc | $31.46 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147982956 | CMS |
| Alexion Pharmaceuticals, Inc. | $18.26 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094040659 | CMS |
| Alnylam Pharmaceuticals Inc. | $22.11 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125852839 | CMS |
| Alnylam Pharmaceuticals Inc. | $28.89 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125852889 | CMS |
| ARGENX US, INC. | $33.35 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142112211 | CMS |
| ARGENX US, INC. | $38.00 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142107735 | CMS |
| ARGENX US, INC. | $32.37 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142108363 | CMS |
| Biogen, Inc. | $28.74 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104876538 | CMS |
| Celgene Corporation | $24.23 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101170478 | CMS |
| Celgene Corporation | $11.76 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101170482 | CMS |
| Celgene Corporation | $12.99 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101170492 | CMS |
| Celgene Corporation | $26.40 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101170496 | CMS |
| Celgene Corporation | $25.07 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101170504 | CMS |
| Celgene Corporation | $10.59 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101170506 | CMS |
| Celgene Corporation | $8.14 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101170508 | CMS |
| Celgene Corporation | $14.06 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101170510 | CMS |
| Eisai Inc. | $25.04 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110730449 | CMS |
| Eisai Inc. | $24.44 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110730451 | CMS |
| Eisai Inc. | $31.75 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110730453 | CMS |
| EMD Serono, Inc. | $35.07 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120237568 | CMS |
| EMD Serono, Inc. | $33.91 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120250595 | CMS |
| Lilly USA, LLC | $23.08 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136049731 | CMS |
| Lilly USA, LLC | $28.11 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136041828 | CMS |
| Lilly USA, LLC | $0.54 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136045123 | CMS |
| Lilly USA, LLC | $25.64 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136045121 | CMS |
| Lilly USA, LLC | $29.12 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136047239 | CMS |
| Lilly USA, LLC | $28.95 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136041830 | CMS |
| Lundbeck LLC | $33.38 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145941652 | CMS |
| Lundbeck LLC | $34.22 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145941654 | CMS |
| Neurelis, Inc. | $24.41 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145647306 | CMS |
| Novartis Pharmaceuticals Corporation | $24.49 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087148508 | CMS |
| Novartis Pharmaceuticals Corporation | $27.49 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087148518 | CMS |
| PFIZER INC. | $26.19 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131671454 | CMS |
| Teva Pharmaceuticals USA, Inc. | $15.10 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151468518 | CMS |
| UCB, Inc. | $32.32 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143500506 | CMS |
| UCB, Inc. | $26.97 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143500511 | CMS |
| UCB, Inc. | $24.04 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143500515 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.